Novartis's FLAME Rockets LAMA/LABAs Into COPD Limelight At GSK's Expense
Novartis's recent publication of data from its FLAME study comparing its Ultibro Breezhaler with GSK's Advair/Seretide in reducing COPD exacerbations could lead to a change in guidelines to favor LAMA/LABAs over ICS/LABA products in patients with severe COPD. Boehringer Ingelheim's popular Stiolto Respimat will benefit from FLAME's good will, but GSK's son-of-Advair, Breo, will likely suffer.
You may also be interested in...
While GSK and collaborators publish findings from the IMPACT trial comparing once-daily single-inhaler triple versus dual therapy in patients with COPD in NEJM, two clinicians in an accompanying editorial argue that the trial falls short of providing robust evidence for switching strategy.
Sunovion has secured US rights to Novartis's respiratory inhalers, and will cash in on Novartis's FLAME data in COPD patients which recently helped change treatment guidelines.
There has been some criticism of the recent update to COPD management guidelines published by GOLD, with concern over the how much of the changes are based on clinical evidence.